At the turn of the century Abel, Rowntree, and Turner reported on an extracorporeal blood purification procedure they called plasmapheresis, which is the first time this terminus appears within the scientific community. The continuous flow plasmapheresis known today, had a significant contribution towards the development of cell separators and plasma filters in the early 1970s (1-4). Since then, the terms plasmapheresis and plasma exchange have been used interchangeably, describing an extracorporeal blood fractionation procedure with replacement of the plasma fraction. The fascinating idea of being able to remove potentially pathogenic plasma constituents with a less invasive technical procedure, leads to widespread use of plasmapheresis, and a large number of publications suggests that it has been considered in almost every life threatening systemic disease. Meanwhile, the conduction of numerous clinical trials has led to a substantial body of evidence, supporting beneficial clinical effects of plasma exchange in a number of disorders (1). In cases of lupus nephritis, rapidly progressive glomerulonephritis concomitant to a variety of diseases, and rheumatoid arthritis, elimination of autoantibodies (AAB) and circulating immune complexes (CIC) has been considered a key issue (2-4). In fact, pathogenic plasma constituents distributed within the intravascular compartment or with quick redistribution from the extravascular into the intravascular compartment, can be removed very effectively. Another mode of action (that could be operative in the treatment of hemolytic uremic syndrome and/or thrombotic thrombocytopenic purpura) is the substitution of a defective metalloproteinase that cleaves Willebrand factor multimers by plasma exchange against fresh frozen or cryodepleted plasma (5, 6). Generally in plasma exchange, depending on the nature of the substitution solution, patients may experience major intolerance reactions (1, 6). The risk of transmitting infectious diseases, though of minor relevance in life threatening disease, must also be taken into account.
The attempt to improve the extracorporeal elimination of AAB and CIC without the drawback of plasma protein substitution has led to the development of immunoadsorption systems on the basis of "in vivo affinity chromatography". Although these systems vary in the degree of their selectivity, they have the advantage of saving albumin, immunoglobulins, coagulation, and complement factors (7, 8). Some systems allow the processing of several plasma volumes, thus increasing elimination rates without major side effects or the need for plasma protein substitution (7, 9, 10) .
A number of systems are currently approved in the United States, the European Community, and other regions of the world. The adsorber columns contain fillings based on silica (Cypress Biotech, Prosorba, Ligand: Protein A) or polyvinylethanol (Asahi, Immusorba, Ligand: Hydrophobic amino acids), or they use carrier material that can be regenerated and reused on a sepharose basis with either protein A (Excorim AB , Immunosorba) or sheep anti-human immunoglobulin (Therasorb, IG-Therasorb) as ligands (7, [11] [12] [13] . Not surprisingly the systems vary considerably in their capacity and affinity for pathogens, so that the results of clinical studies are not easily compared.
In the following sections, some of the systems already in use, but also upcoming highly selective concepts will be discussed in order of increasing selectivity.
Membrane differential filtration
Although technically not an immunoadsorption system, membrane differential filtration (MDF, synonyms: cascade filtration or double filtration) will be discussed here, since its selectivity is comparable to less specific immunoadsorption procedures (14, 15) . After separation from whole blood, plasma is fractionated by a second membrane with pore sizes ranging from 0.013 µm to 0.037 µm (16) . Depending also on the nature of the filter polymer, plasma fractionators with a variety of seiving coefficients for their target proteins are commercially available (16) . They can be used from the lower molecular range for more or less selective elimination of IgG (approx. 150 kD) up to the elimination of the larger low-density-lipoprotein (LDL, approx. 2000 kD). In many documented cases of autoimmune diseases, AAB and CIC blood levels were reduced by MDF (15) . Obviously elimination characteristics depend on the properties of the plasma fractionator. Systematic documentation also exists in the case of cryofiltration, a modified MDF procedure in which
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The International Journal of Artificial Organs / Vol. 24 / no. 1, 2001/ pp. 4-7 Selective apheresis -time for a change plasma is cooled down to 4°C before fractionation in a specially designed cryofilter (17) . In the type II cryoglobulinemia that sometimes accompanies hepatitis C infection, CIC containing hepatitis C virus are responsible for the symptoms. They can be readily eliminated by cryofiltration (17) .
Adsorption using hydrophobic amino acids
Indications for extracorporeal plasma therapy using the Immusorba columns (TR-350 and PH-350, Asahi Medical, Tokyo, Japan) include neurological autoimmune diseases such as myasthenia gravis and Guillain-Barré syndrome, and also autoimmune diseases such as systemic lupus erythematosus (SLE) (11) . The columns are based on either tryptophane or phenylalanine immobilized on a polyvinyl ethanol gel. The ligand phenylalanine develops a physicochemical affinity to CIC and the PH-350 Immusorba column has been used successfully in the treatment of SLE patients eliminating anti-dsDNA antibodies and CIC (12) . The TR-350 column is often used in the treatment of acute crisis in myasthenia gravis (11, 12) .
Adsorption using protein A
In vitro staphylococcal protein A binds with high affinity to the hinge region between the CH II and CH III domains within the F(c)-Segments of IgG1, IgG2 and IgG4 molecules. In addition, about 30% of the IgG3, IgM and IgA molecules are bound specifically by VH III -regions.
Considerable data from clinical queries has been accumulated for protein A coupled to sepharose (Immunosorba, Excorim AB, Lund, Sweden) and to silica (Prosorba, Cypress Bioscence Inc., San Diego, California) (7, 9, 18, (19) (20) (21) (22) (23) (24) (25) .
A major feature of the Iimmunosorba system is its almost unlimited adsorption capacity. Two columns are installed in parallel -one is perfused with plasma while the other is regenerated -leading to the theoretical possibility of treating an unlimited plasma volume. In practice, during the course of a session, efficiency declines with the processed plasma because of rapid elimination of intravascular immunoglobulins and consecutive gradient formation between the extravascular and the plasma compartment. Every column switch also involves an elution procedure, during which plasma is diluted and a certain amount of plasma proteins is lost. Despite these considerations the double column systems are to date the most powerful semiselective alternatives to plasma exchange. They have been used to remove 1) HLAantibodies before transplantation and in acute vascular rejection; 2) heterologous and autologous factor VIII antibodies; 3) anti-proteinase 3 antibodies in Wegener's granulomatosis; 4) anti-collagen type IV antibodies in Goodpasture's syndrome; 5) a number of other autoimmune diseases with a clearcut connection between autoantibody and disease (7, 9, (18) (19) (20) (21) .
Unlike the double column systems, Prosorba is configured for the treatment of only 1250 ml of plasma. First promising results in the 1980's in the extracorporeal treatment of cancer could not be confirmed later (23, 24) and in the meantime the system has been approved in the United States and Europe for the treatment of idiopathic thrombocytopenic purpura and rheumatoid arthritis based on a unique prospective, controlled, and double blinded clinical study (25) .
It is somewhat intriguing that the mode of action of both protein A-based systems cannot be explained solely by the removal of AAB or CIC. With the Prosorba system, neither the processed plasma volume nor the length of interval between sessions allow significant removal of immunoglobulins. On the other hand, our investigations suggest that intracytoplasmic type 1 and type 2 T-cell cytokine production is altered upon immunoadsorption with double column systems (26) . It seems necessary to postulate that an unknown immunomodulatory pathway is at least in part responsible for the clinical effect of protein A immunoadsorption.
Adsorption using C1q
The native plasma complement factor C1 is a complex heteromultimer consisting of the components C1q, C1r and C1s. Hexameric C1q is composed of 18 polypeptide chains and, in its quaternary structure, appears like a bundle of tulips (27) . The isloated "head" of C1q expresses specific binding to Fc-regions of immunoglobulins. Affinity can be increased by the factor 10,000 when immunoglobulins aggregate on an antigenic surface, where multipoint attachment becomes possible. The phenomenon leads to specific high-affinity binding of circulating immune complexes in C1q-immunoadsorption columns (MIRO, Fresenius, St. Wendel, Germany). In addition, several other plasma constituents are bound to the collagen-like-region of the molecule, including fibrinogen and fibronectin (27) . First clinical trials of the new product indicate beneficial clinical effects in SLE and especially in lupus nephritis (27, 28) .
Adsorption using peptides
Characteristic autoantibody epitopes within a protein often consist of only a few amino acids. In many cases bioengineered peptide constructs bind with comparable affinity to the corresponding antibody.
The R&D activities of Affina Immuntechnik GmbH, Berlin, are focusing on the development of adsorbers for the specific elimination of defined AAB. The adsorbers contain matrices with covalently coupled synthetic peptides which mimic epitopes of autoantigens involved in the corresponding diseases. The first product currently under clinical trial at the German Heart Center Berlin is tailored for depleting AABs against the ß1-adrenergic receptor, which participate in pathogenesis of dilated cardiomyopathy. Dilated cardiomyopathy -a major cause of heart transplantation -is characterised by a progressive dilatation of the left ventricle leading to loss of organ function. The highly specific peptide-based elimination of the responsible AAB may prove a successful treatment for this life threatening disease (29, 30 
